Pulmonx (LUNG) 2024 Wells Fargo Healthcare Conference summary

Leadership insights and strategic focus

• New CEO and CFO have prioritized driving utilization and improving patient workflow, especially at larger medical centers with established emphysema programs.

• Emphasis on building comprehensive treatment programs and demonstrating economic value to hospital administration to secure investment in coordinators and workflow improvements.

• CEO has personally invested in company stock, citing undervaluation and confidence in future growth.

• Leadership is actively involved in field operations and program development, focusing on long-term growth and patient identification strategies.

Financial performance and guidance

• Achieved 30% growth in Q1 and 21% in Q2 of 2024, with reaffirmed guidance and stable turnover despite management changes.

• Revenue growth is considered the primary productivity metric, as utilization reporting is deemed incomplete due to changing customer and ordering patterns.

• Guidance for the second half of 2024 is conservative due to uncertainty around Q3 seasonality and vacation schedules.

• Management maintains confidence in reaching break-even with current cash, supported by ongoing revenue growth and margin improvement initiatives.

Market expansion and clinical development

• Marketing efforts generated 20,000 initial patient contacts in H1 2024, with targeted advertising in regions with strong workflows.

• Two major clinical trials are ongoing: a Japanese post-approval study (enrollment to end in early 2026) and CONVERT-2, with plans for a full Japan launch in 2026.

• CONVERT-1 trial data shows high conversion rates and significant patient benefit, supporting a potential step-function expansion of the addressable market.

• AeriSeal has EU MDR approval, with international launch expected in 2026 post-CONVERT-2 enrollment and follow-up.